<DOC>
	<DOC>NCT01084161</DOC>
	<brief_summary>To determine the analgesic efficacy, duration of effect, and safety of single doses of N1539 in subjects undergoing open abdominal hysterectomy</brief_summary>
	<brief_title>Study to Evaluate the Efficacy, Safety and Tolerability of N1539</brief_title>
	<detailed_description />
	<mesh_term>Morphine</mesh_term>
	<criteria>moderate to severe pain with VAS of &gt;/= 45 mm undergo open abdominal hysterectomy ASA I or II signed ICF BMI &gt;18.5 and &lt; 31.5 kg/m^2 suspected metastatic cervical or endometrial cancer prior abdominal surgery with postoperative complications active pancreatitis, obstruction of biliary tree or total bilirubin&gt; 2.5 mg/dL active GI bleeding, or peptic ulcer disease unstable medical condition HbA1c &gt;9.5 or uncontrolled diabetes SBP &gt;150 mmHg or DBP &gt; 95 mmHg personal or familial contraindication to undergoing general anesthesia Antihypertensive agents or diabetic regimen that is not stable (4 weeks prior to surgery) taking CNS agents for pain acetaminophen or NSAIDs not discontinued for at least 5 halflives prior to planned surgery currently taking an opioid or has taken an opioid chronically for pain in past 2 years corticosteroid or systemic corticosteroids within 6 weeks of planned surgery has a known bleeding disorder or taking agents affecting coagulation history of intolerance or allergic reactions to NSAIDs, COX2 inhibitors, aspirin and other salicylates receiving lithium or a combination of furosemide with an ACE inhibitor or angiotensin receptor blocker Known to have sleep apnea History of hepatitis B or C AST or ALT &gt; 2 times the upper limit of normal Known or suspected COPD with retention of carbon dioxide psychiatric condition that impairs the capability of the subject to report pain</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2011</verification_date>
</DOC>